The Patent Finder

Cell for Use in Immunotherapy Which Contains Modified Nucleic Acid Construct Encoding Wilms Tumor Gene Product or Fragment Thereof, Method for Producing Said Cell, and Said Nucleic Acid Construct

RIKEN

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 3 of these applications claim priority to application PCT/JP2012/069377, filed Jul 30, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 10,316,332Cell for Immunotherapy, Including Modified Nucleic Acid Construct Encoding Wilms Tumor Gene Product
In force
 · Medium confidence
RIKENIn force
Medium confidence
US 11,072,802Cell for Immunotherapy, Including Modified Nucleic Acid Construct Encoding Wilms Tumor Gene Product
In force
 · Medium confidence
RIKENIn force
Medium confidence
US 9,783,821Cell for Use in Immunotherapy Which Contains Modified Nucleic Acid Construct Encoding Wilms Tumor Gene Product or Fragment Thereof, Method for Producing Said Cell, and Said Nucleic Acid Construct
In force
 · High confidence
RIKENIn force
High confidence
Application 15/708,900Cell for Use in Immunotherapy Which Contains Modified Nucleic Acid Construct Encoding Wilms Tumor Gene Product or Fragment Thereof, Method for Producing Said Cell, and Said Nucleic Acid Construct
Abandoned
Abandoned Apr 12, 2018
RIKENAbandonedAbandoned Apr 12, 2018
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by RIKEN.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited